Results 181 to 190 of about 48,908 (228)
Some of the next articles are maybe not open access.
Annals of internal medicine, 1976
In 1971, rifampin was approved for treatment of pulmonary tuberculosis and asymptomatic carriers of Neisseria meningitidis. At present, the approved indications remain the same. However, rifampin in conjunction with at least one other antituberculous drug may be of great value in therapy of extrapulmonary tuberculosis and infections due to other ...
Gian G. Gallo, Pietro Radaelli
openaire +3 more sources
In 1971, rifampin was approved for treatment of pulmonary tuberculosis and asymptomatic carriers of Neisseria meningitidis. At present, the approved indications remain the same. However, rifampin in conjunction with at least one other antituberculous drug may be of great value in therapy of extrapulmonary tuberculosis and infections due to other ...
Gian G. Gallo, Pietro Radaelli
openaire +3 more sources
International Journal of Dermatology, 1993
Rifampicin (Rp) is a semisynthetic derivative of Rifamycin B, an antimicrobial agent produced by Streptomyces mediterranei. Rp is a broad spectrum antimicrobial and inhibits the growth of most Gram-positive bacteria, as well as many Gram-negative microorganisms, such as Escherichia coli, Pseudomonas, indole-positive and indole-negative Proteus, and ...
N K, Tsankov, J A, Kamarashev
openaire +2 more sources
Rifampicin (Rp) is a semisynthetic derivative of Rifamycin B, an antimicrobial agent produced by Streptomyces mediterranei. Rp is a broad spectrum antimicrobial and inhibits the growth of most Gram-positive bacteria, as well as many Gram-negative microorganisms, such as Escherichia coli, Pseudomonas, indole-positive and indole-negative Proteus, and ...
N K, Tsankov, J A, Kamarashev
openaire +2 more sources
Pediatrics In Review, 1996
Rifampin is a semisynthetic derivative of rifamycin B that is active against a wide range of microorganisms and bactericidal for extracellular as well as intracellular pathogens. Most gram-positive and many gram-negative bacteria, as well as mycobactenia, are inhibited by nifampin.
openaire +2 more sources
Rifampin is a semisynthetic derivative of rifamycin B that is active against a wide range of microorganisms and bactericidal for extracellular as well as intracellular pathogens. Most gram-positive and many gram-negative bacteria, as well as mycobactenia, are inhibited by nifampin.
openaire +2 more sources
JAMA: The Journal of the American Medical Association, 1972
To the Editor.— Rifampin is an effective antituberculous drug recently approved by the Food and Drug Administration for general use. Users are warned that Rifampin has been shown to produce liver dysfunction. There have been fatalities associated with jaundice in patients with liver disease or receiving rifampin concomitantly with other hepatotoxic ...
openaire +2 more sources
To the Editor.— Rifampin is an effective antituberculous drug recently approved by the Food and Drug Administration for general use. Users are warned that Rifampin has been shown to produce liver dysfunction. There have been fatalities associated with jaundice in patients with liver disease or receiving rifampin concomitantly with other hepatotoxic ...
openaire +2 more sources
TO RIFAMPIN OR NOT TO RIFAMPIN?!
Journal of the American College of Cardiology, 2022Faysal Alhasan +2 more
openaire +1 more source
Interaction of Rifampin and Chlorpropamide
Chest, 1980A 62-year-old man who had been taking 250 mg of chlorpropamide daily for several years received rifampin concomitantly and had a subsequent increased dosing requirement of chlorpropamide. When rifampin was discontinued several months later, the serum chlorpropamide concentration rose dramatically.
T H, Self, T, Morris
openaire +2 more sources
Archives of Internal Medicine, 1984
Rifampin, an antituberculosis agent, is usually administered for nine to 12 months with other antituberculosis drugs or drugs from other classes. A potential for drug interactions often exists because this drug is a potent inducer of drug metabolism. Rifampin causes a proliferation of the smooth endoplasmic reticulum and an increase in the cytochrome P-
A M, Baciewicz, T H, Self
openaire +2 more sources
Rifampin, an antituberculosis agent, is usually administered for nine to 12 months with other antituberculosis drugs or drugs from other classes. A potential for drug interactions often exists because this drug is a potent inducer of drug metabolism. Rifampin causes a proliferation of the smooth endoplasmic reticulum and an increase in the cytochrome P-
A M, Baciewicz, T H, Self
openaire +2 more sources
Corneal Penetration of Rifampin
American Journal of Ophthalmology, 1977We tested the corneal penetration of rifampin in four vehicles: dimethylsulfoxide, polyethylene glycol, an ocular lubricant, and as rifampin ointment. We measured drug concentrations in the aqueous humor in rabbits after topical instillation of 1 and 2.5% rifampin according to two dosage schedules.
M F, Feldman, R A, Moses
openaire +2 more sources